221 related articles for article (PubMed ID: 28222061)
1. Crisaborole (Eucrisa) for atopic dermatitis.
Med Lett Drugs Ther; 2017 Feb; 59(1515):34-35. PubMed ID: 28222061
[No Abstract] [Full Text] [Related]
2. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
3. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
[TBL] [Abstract][Full Text] [Related]
4. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor.
Pao-Ling Lin C; Gordon S; Her MJ; Rosmarin D
J Am Acad Dermatol; 2019 May; 80(5):1451-1453. PubMed ID: 30395914
[No Abstract] [Full Text] [Related]
6. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
[TBL] [Abstract][Full Text] [Related]
8. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
9. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
[TBL] [Abstract][Full Text] [Related]
10. Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis.
Castelli G; Schaffer M
Am Fam Physician; 2018 Sep; 98(6):379-380. PubMed ID: 30215912
[No Abstract] [Full Text] [Related]
11. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
12. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
Ciaravino V; Coronado D; Lanphear C; Chanda S
J Dermatol Sci; 2017 Aug; 87(2):116-122. PubMed ID: 28416366
[TBL] [Abstract][Full Text] [Related]
13. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
14. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Purohit V; Riley S; Tan H; Ports WC
J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
[TBL] [Abstract][Full Text] [Related]
17. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
18. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA
Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
